Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study)
Abstract Background Despite the introduction of combined antiretroviral therapy, the clinical outcomes of HIV-associated Burkitt lymphoma (BL) remain poor. Methods To evaluate the clinical characteristics, prognostic factors, and outcomes of HIV-associated BL, we conducted a retrospective analysis o...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Infectious Agents and Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13027-023-00559-y |
| _version_ | 1797398130520489984 |
|---|---|
| author | Jinrong Zhao Haiyan Min Yunhong Huang Yaokai Chen Min Wang Lirong Xiao Guo Wei Yan Wu Yao Liu Wei Zhang |
| author_facet | Jinrong Zhao Haiyan Min Yunhong Huang Yaokai Chen Min Wang Lirong Xiao Guo Wei Yan Wu Yao Liu Wei Zhang |
| author_sort | Jinrong Zhao |
| collection | DOAJ |
| description | Abstract Background Despite the introduction of combined antiretroviral therapy, the clinical outcomes of HIV-associated Burkitt lymphoma (BL) remain poor. Methods To evaluate the clinical characteristics, prognostic factors, and outcomes of HIV-associated BL, we conducted a retrospective analysis of patients from multiple centers in China. Results The study included 41 patients from 8 medical centers. Among the included population, male patients accounted for 87.8%, with 75.6% in advanced stages. Notably, 46.3% of cases involved bone marrow, while 19.5% involved the central nervous system (CNS). The most commonly used chemotherapy regimen was DA-EPOCH ± R, accounting for 53.6% of cases. The overall response rates for patients receiving DA-EPOCH ± R and R-Hyper-CVAD were 59% and 58.2%, respectively. Interestingly, patients receiving regimens containing rituximab had similar complete remission rates (25% vs. 23.5%) and overall survival time (45.69 ± 11.58 vs. 47.79 ± 11.72 months, P = 0.907) compared to those without rituximab, but differed in progression rates (33.3% vs. 47.1%). For the entire cohort, the 1-year progression-free survival (PFS) and overall survival (OS) rates were 52% and 67%, respectively. CNS involvement was independent risk factors for survival, with 1-year PFS and OS rates of 0% and 38% for patients with CNS involvement, and PFS and OS rates of 66% and 75% for patients without CNS involvement. Conclusions HIV-associated BL patients in China have poor prognosis and show limited response to current treatment regimens. The absence of CNS involvement significantly improves clinical outcomes. The use of rituximab is not significantly associated with improved outcomes but can reduce disease progression. |
| first_indexed | 2024-03-09T01:21:16Z |
| format | Article |
| id | doaj.art-33788fb1258e4ec991e80ab6ee6ba6a1 |
| institution | Directory Open Access Journal |
| issn | 1750-9378 |
| language | English |
| last_indexed | 2024-03-09T01:21:16Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Agents and Cancer |
| spelling | doaj.art-33788fb1258e4ec991e80ab6ee6ba6a12023-12-10T12:08:11ZengBMCInfectious Agents and Cancer1750-93782023-12-011811810.1186/s13027-023-00559-yClinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study)Jinrong Zhao0Haiyan Min1Yunhong Huang2Yaokai Chen3Min Wang4Lirong Xiao5Guo Wei6Yan Wu7Yao Liu8Wei Zhang9Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical SciencesYunnan Provincial Hospital of Infectious DiseasesAffiliated hospital of guizhou medical universityChonqging Public Health Medical CenterThe First Hospital of ChangshaHenan Infectious Disease Hospital, The Sixth People’s Hospital of ZhengzhouPublic health clinical center of ChengduHenan Infectious Disease Hospital, The Sixth People’s Hospital of ZhengzhouDepartment of Hematology Oncology, Chongqing University Cancer HospitalDepartment of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical SciencesAbstract Background Despite the introduction of combined antiretroviral therapy, the clinical outcomes of HIV-associated Burkitt lymphoma (BL) remain poor. Methods To evaluate the clinical characteristics, prognostic factors, and outcomes of HIV-associated BL, we conducted a retrospective analysis of patients from multiple centers in China. Results The study included 41 patients from 8 medical centers. Among the included population, male patients accounted for 87.8%, with 75.6% in advanced stages. Notably, 46.3% of cases involved bone marrow, while 19.5% involved the central nervous system (CNS). The most commonly used chemotherapy regimen was DA-EPOCH ± R, accounting for 53.6% of cases. The overall response rates for patients receiving DA-EPOCH ± R and R-Hyper-CVAD were 59% and 58.2%, respectively. Interestingly, patients receiving regimens containing rituximab had similar complete remission rates (25% vs. 23.5%) and overall survival time (45.69 ± 11.58 vs. 47.79 ± 11.72 months, P = 0.907) compared to those without rituximab, but differed in progression rates (33.3% vs. 47.1%). For the entire cohort, the 1-year progression-free survival (PFS) and overall survival (OS) rates were 52% and 67%, respectively. CNS involvement was independent risk factors for survival, with 1-year PFS and OS rates of 0% and 38% for patients with CNS involvement, and PFS and OS rates of 66% and 75% for patients without CNS involvement. Conclusions HIV-associated BL patients in China have poor prognosis and show limited response to current treatment regimens. The absence of CNS involvement significantly improves clinical outcomes. The use of rituximab is not significantly associated with improved outcomes but can reduce disease progression.https://doi.org/10.1186/s13027-023-00559-yAIDSLymphomaBurkittOutcomeChinaHuman immunodeficiency virus |
| spellingShingle | Jinrong Zhao Haiyan Min Yunhong Huang Yaokai Chen Min Wang Lirong Xiao Guo Wei Yan Wu Yao Liu Wei Zhang Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study) Infectious Agents and Cancer AIDS Lymphoma Burkitt Outcome China Human immunodeficiency virus |
| title | Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study) |
| title_full | Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study) |
| title_fullStr | Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study) |
| title_full_unstemmed | Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study) |
| title_short | Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study) |
| title_sort | clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus associated burkitt lymphoma the central and western china aids lymphoma league 002 study call 002 study |
| topic | AIDS Lymphoma Burkitt Outcome China Human immunodeficiency virus |
| url | https://doi.org/10.1186/s13027-023-00559-y |
| work_keys_str_mv | AT jinrongzhao clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT haiyanmin clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT yunhonghuang clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT yaokaichen clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT minwang clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT lirongxiao clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT guowei clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT yanwu clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT yaoliu clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study AT weizhang clinicalcharacteristicsandoutcomesofnewlydiagnosedpatientswithhumanimmunodeficiencyvirusassociatedburkittlymphomathecentralandwesternchinaaidslymphomaleague002studycall002study |